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HIV-1 Nef is required for efﬁcient viral replication and pathogenesis. However, the extent to which
Nef’s functions are maintained in natural sequences during chronic infection, and their clinical
relevance, remains incompletely characterized. Relative to a control Nef from HIV-1 strain SF2, HLA
class I and CD4 down-regulation activities of 46 plasma RNA Nef sequences derived from unique
chronic infected individuals were generally high and displayed narrow dynamic ranges, whereas
Nef-mediated virion infectivity, PBMC replication and CD74 up-regulation exhibited broader
dynamic ranges. 80% of patient-derived Nefs were active for at least three functions examined.
Functional co-dependencies were identiﬁed, including positive correlations between CD4 down-
regulation and virion infectivity, replication, and CD74 up-regulation, and between CD74 up-
regulation and PBMC replication. Nef-mediated virion infectivity inversely correlated with patient
CD47 T-cell count. Strong functional co-dependencies and the polyfunctional nature of patient-
derived Nef sequences suggest a phenotypic requirement to maintain multiple Nef functions during
chronic infection.
& 2013 Elsevier Inc. All rights reserved.Introduction
The highly variable HIV-1 Nef protein is required for efﬁcient
viral replication and disease progression in vivo (Deacon et al.,
1995; Kestler et al., 1991; Kirchhoff et al., 1995). Nef exhibits
multiple functions in vitro, including enhancement of virion
infectivity and replication (Mu¨nch et al., 2007; Miller et al.,
1994), down-regulation of cell-surface CD4 (Aiken et al., 1994;
Garcia and Miller, 1991) and HLA class I (HLA-I) (Collins et al.,
1998; Schwartz et al., 1996), up-regulation of HLA class II
associated invariant chain (CD74) (Schindler et al., 2003;
Stumptner-Cuvelette et al., 2001), and others (Das and Jameel,
2005; Heigele et al., 2012; Kirchhoff et al., 2008). Variation in Nef
activity has been demonstrated for laboratory-adapted viral
strains (Fackler et al., 2006; Keppler et al., 2006), viral quasispe-
cies within a single individual (Ali et al., 2009; Lewis et al., 2008),ll rights reserved.
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ding authors, respectively.and small numbers of clinically isolated sequences (Na et al.,
2004; Zuo et al., 2012), including those from long-term nonpro-
gressors (Corro et al., 2012; Premkumar et al., 1996; Tobiume
et al., 2002) and patients with advanced infection (Carl et al.,
2001). However, the functional breadth of naturally occurring Nef
variants have not been comprehensively assessed using panels of
clinically derived sequences. Here, we assessed ﬁve key Nef
functions (enhancement of virion infectivity and replication
capacity in PBMC, down-regulation of cell surface CD4 and HLA-
I, and up-regulation of CD74) using 46 clonal nef sequences from
unique chronic HIV-1-infected individuals. We examined the
dynamic ranges, co-dependence, and clinical correlates of these
ﬁve Nef activities.Results and discussion
Genotypic and phenotypic proﬁle of patient-derived Nef sequences
We analyzed plasma HIV-1 RNA sequences, as these repre-
sent the current replicating virus better than proviral DNA
(Crotti et al., 2006). Patient Nef sequences displayed no major
phylogenetic clustering (Supplemental Fig. 1). Codon-speciﬁc
P. Mwimanzi et al. / Virology 439 (2013) 74–80 75Shannon entropy scores of the patient-derived Nef clonal
sequences (N¼46) correlated signiﬁcantly with those of 1191
subtype B sequences retrieved from the Los Alamos data-
base (Spearman R¼0.92, po0.0001), suggesting them to beFig. 1. Western blot and functional proﬁle of 46 patient-derived Nef proteins. (A) Rep
intensities relative to SF2 control, using rabbit (left), sheep (middle), and maximum of
ranges of ﬁve Nef-mediated activities: infectivity (IFV), viral replication (VRC), HLA-I dow
assay was normalized to that of control Nef strain SF2, which was considered as 100% (d
range (edges of box) and range (whiskers) of functions for N¼46 chronic patient-derive
Nef, a polyfunctionality score was developed. For each of the ﬁve Nef activities tested,
while those below this cutoff were deﬁned as ‘‘poor’’. The number outside the pie c
indicates the number of patient-derived Nef sequences exhibiting this score. (E) Individ
clinical disease in this population of chronic patients. An inverse correlation was o
(R¼0.338, p¼0.02; Spearman‘s correlation). (F) An inverse association was also ob
p¼0.03; Spearman‘s correlation).representative of subtype B sequence diversity. All patient-
derived and SF2 Nef proteins were examined by Western
blot using two independent anti-Nef primary antibodies
(representative data shown in Fig. 1A). No major differences inresentative blots of DNef, SF2 Nef, and four patient-derived Nef clones (B) Band
rabbit/sheep combined (right), for each patient-derived Nef. (C) In vitro dynamic
n-regulation, CD74 up-regulation, and CD4 down-regulation. Nef function in each
otted line). Box and whisker plots show the median (horizontal line), interquartile
d Nef clones. (D) To assess combined functional differences of each patient-derived
functions above the 33rd percentile of the population were deﬁned as ‘‘adequate’’
hart indicates the ‘‘polyfunctionality score’’, while the number within each slice
ual Nef functions and the Nef polyfunctionality score were compared to markers of
bserved between Nef-mediated viral infectivity and patient CD4þ T cell count
served between Nef polyfunctionality score and CD4þ T cell count (R¼0.307,
Table 1
Analysis of Nef residues associated with functions.
Nef activity Codona AAb No. of
subjectsc
Relative Nef
activity
p-
value
q-
value
AAþ AA AAþ AA
Viral infectivity 8 R 18 25 107.0 140.1 0.02 0.2
10 L 5 34 82.8 116.4 0.01 0.2
10 V 8 31 146.0 107.0 0.005 0.2
21 R 32 14 131.9 97.8 0.02 0.2
49 A 36 8 122.4 85.7 0.008 0.2
85 F 7 39 94.3 121.2 0.02 0.2
152 Q 5 40 76.7 120.2 0.002 0.2
Viral replication in
PBMC
10 M 8 31 104.9 69.5 0.001 0.1
135 F 8 38 116.8 69.7 0.008 0.2
135 Y 38 8 69.7 116.8 0.008 0.2
182 Q 6 40 26.3 80.4 0.001 0.1
194 M 17 29 60.7 84.9 0.003 0.1
194 V 21 25 93.8 69.5 0.005 0.2
CD74 up-regulation 12 E 5 41 195.1 102.9 0.01 0.2
21 Q 6 40 180.9 98.1 0.01 0.2
94 K 40 6 124.4 52.9 0.004 0.1
205 D 21 25 150.5 82.1 0.001 0.02
205 N 25 21 82.1 150.5 0.001 0.02
a HXB2 numbering.
b AA, amino acid.
c Gaps in the alignment are not counted; as such, amino acid totals do not
always add up to 46.
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(Fig. 1B).
Functional characterization of patient-derived Nef sequences
All 46 patient-derived Nef proteins exhibited at least partial
activity for all functions tested (Fig. 1C and Supplemental Fig. 2).
Relative to a control Nef, derived from HIV-1 strain SF2, patient-
derived Nef sequences were generally highly functional with
respect to down-regulation of HLA-I and CD4, while dynamic
ranges of other Nef functions were broader (Fig. 1C). Median
[IQR] Nef activities, normalized to those of SF2 control, were:
virion infectivity, 116% [88–160]; viral replication capacity, 76%
[57–98]; HLA-I down-regulation, 106% [98–112]; CD74 up-regula-
tion, 112% [69–151]; and CD4 down-regulation, 99% [92–102]
(Fig. 1C). Aligned amino acid sequences and functional activities
of the 46 patient-derived clonal nef sequences are shown in
Supplemental Table 1.
The relatively conserved CD4 down-regulation function
observed in our cohort is consistent with most previous studies
of chronic Nef sequences (Agopian et al., 2007; Carl et al., 2001;
Zuo et al., 2012). Similar preservation of HLA-I down-regulation
function has also been reported by some studies (Noviello et al.,
2007; Zuo et al., 2012), however others have observed wider
ranges in chronic infection (Lewis et al., 2008) or inefﬁcient
Nef-mediated HLA-I down modulation in later infection stagesFig. 2. Co-dependence between in vitro Nef activities. Pairwise associations between each of the ﬁve in vitro functions were examined for the patient-derived Nef clones.
Signiﬁcant correlations were observed between CD4 down-regulation and infectivity, viral replication, and CD74 up-regulation; and between CD74 up-regulation and viral
replication (all po0.05, Spearman‘s correlation).
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ment of virion infectivity was relatively well preserved among
chronic patient-derived sequences, while Nef-mediated viral
replication capacity was on average lower than the SF2 control
strain, is perhaps notable since previous studies of these Nef
activities have failed to observe consistent associations with
clinical status (Carl et al., 2000; Crotti et al., 2006; Tobiume
et al., 2002). Nef function can be inﬂuenced by the choice of assay
systems, cell lines, and control strain used (Kirchhoff et al., 2008;
Mwimanzi et al., 2011; Suzu et al., 2005); these factors, combined
with the smaller number of patients previously studied, may
explain some of these divergent results.
Taken together, our data support CD4 and HLA-I down-regula-
tion as essential in vivo functions during chronic HIV-1 infection. In
contrast, the broader dynamic ranges of virion infectivity, replica-
tion capacity in PBMC, and CD74 up-regulation may suggest
differential requirements for these activities in maintaining viral
ﬁtness during chronic infection. Alternatively, some functions may
serve as surrogates of other Nef activities not assessed, such as
modulation of cellular activation. Indeed, an association between
CD74 up-regulation and polyclonal T-cell activation was recently
demonstrated in HIV-infected subjects, suggesting that Nef could
mediate this effect directly or indirectly through CD74 up-
regulation in virus-infected cells (Ghiglione et al., 2012). None-
theless, our results extend our understanding of Nef functions that
facilitate viral replication and immune evasion in naturally occur-
ring sequences (Brambilla et al., 1999; Casartelli et al., 2003; Crotti
et al., 2006; Foster et al., 2001).
Combined functional analyses: Nef polyfunctionality score
To investigate the extent to which individual patient-derived
Nef proteins maintained multiple functions simultaneously, we
deﬁned a ‘‘polyfunctionality’’ score ranging from 0 (all functions
relatively poor) to 5 (all functions adequate) where the 33rd
percentile of each function was deﬁned as the cutoff between
these two categories (Fig. 1D). More than half (27 of 46) of patient-
derived Nefs exhibited a polyfunctionality score Z4 whereas 19.6%
(9 of 46) exhibited a score r2. Two Nef clones scored 0 although
both had functional activities 410th percentile for all ﬁve activities
(Supplemental Table 1), indicating that they were not completely
defective. These results support the importance of maintaining
multiple Nef functions during chronic infection.
Correlation of Nef functions with HIV-1 clinical parameters
A signiﬁcant inverse relationship was observed between Nef-
mediated virion infectivity and CD4þ T-cell count in our cohort
(Spearman‘s R¼0.338, p¼0.02) (Fig. 1E). To our knowledge, this
is a novel observation in chronic infected individuals. Nef poly-
functionality score was also inversely related to CD4þ T-cell
count in our cohort (R¼0.307, p¼0.03) (Fig. 1F), although this
did not remain signiﬁcant after removing infectivity from the
scoring scheme (not shown). Of note, Lewis et al. (2008) pre-
viously reported a relatively broad range of Nef-mediated HLA-I
down-regulation function in eleven chronic infected patients and
positive correlations with CD4þ T-cell counts, whereas our results
showed no relationship between these two parameters. This
difference may be due to the fact that Nef-mediated HLA-I
down-regulation activity was relatively highly preserved in our
cohort (Fig. 1C). No correlation was observed between plasma
viral load and any Nef function or the polyfunctionality score.
Although further studies will be required to elucidate the under-
lying mechanism(s) of our observations, these results suggest an
important role for Nef-mediated virion infectivity in HIV-1
pathogenesis.Nef functional co-dependencies
Mutational studies indicate that the genetic determinants of
Nef‘s various functions are largely distinct from one another, and
that these functions may therefore be considered largely inde-
pendent (Dai and Stevenson, 2010). For instance, CD4 down-
regulation is determined by the highly conserved Nef motifs
LL163,164 and DD174,175, while HLA-I down-regulation is mediated
by other motifs including M20 and PxxP72 (Akari et al., 2000;
Geyer et al., 2001). However, the extent to which secondary
genetic polymorphisms contribute to Nef function, and thus the
extent to which the various activities of patient-derived Nef
sequences are functionally independent, remains incompletely
known (Mwimanzi et al., 2012).
Pairwise correlations of Nef functions in our patient-derived
sequences revealed positive relationships between CD4 down-
regulation and all other activities, except HLA-I down-regulation
(Fig. 2), suggesting shared molecular mechanisms and/or func-
tional complementarity. Indeed, interaction of Nef with the
cellular dileucine-based sorting pathway is required for CD4
down-regulation and optimal viral infectivity (Craig et al.,
1998). Nef point mutants impaired in CD4 down-regulation were
also most delayed in viral replication (Lundquist et al., 2002). A
mechanistic link between Nef-mediated CD4 and CD74 modula-
tion is suggested by the observations that both functions involve
interaction of Nef with AP-2 (Chaudhuri et al., 2007; Mitchell
et al., 2008; Toussaint et al., 2008), and that mutations WL57,58AA
and LL163,164GG lowered both Nef-mediated CD4 down-regulation
and CD74 up-regulation functions (Stumptner-Cuvelette et al.,
2001), although this remains controversial (Toussaint et al.,
2008). Taken together with previous studies, our results suggest
that Nef-mediated CD4 down-regulation functions of patient-
derived sequences may be, at least in part, mechanistically linked
to other Nef functions through common functional motifs and/or
interactions with common host proteins in vivo.
In contrast, HLA-I down-regulation showed no correlation with
any other activity (Fig. 2), suggesting that it may be differentially
regulated in vivo. This observation is consistent with previous studies
of site-directed mutants of laboratory-adapted strains (Akari et al.,
2000; Lundquist et al., 2002; Stoddart et al., 2003). Also consistent
with previous studies using Nef point mutations undertaken in CD4þ
T cells (Lundquist et al., 2002), we observed no correlation between
Nef-mediated viral infectivity and viral replication enhancement in
PBMCs, supporting distinct genetic determinants of these two func-
tions. A recent study observed that HIV-1 gp41 enhanced viral
infection through activation of the CD74 protein-mediated extracel-
lular signal-regulated kinase/mitogen-activated protein kinase path-
way (Zhou et al., 2011), raising the intriguing hypothesis that Nef
might enhance viral infection through the same mechanism. Of note,
no inverse relationships were observed between Nef activities,
arguing against functional tradeoffs or the existence of particular
substitutions or domains that enhance one function at the expense of
another. This is consistent with the maintenance of polyfunctionality
for most patient-derived Nef sequences.
Amino acids associated with Nef functions
Identiﬁcation of highly conserved Nef residues and domains
critically important for Nef‘s various functions has been performed
using mutational studies (Lundquist et al., 2002; Neri et al., 2011;
Stumptner-Cuvelette et al., 2001) and limited analyses of patient-
derived sequences (Glushakova et al., 2001; Lewis et al., 2012). To
investigate the contribution of naturally-occurring polymorphisms at
Nef‘s more variable sites on protein function of patient-derived
sequences, we performed an exploratory sequence-function analysis
restricted to amino acids observed at a minimum frequency of N¼5
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(Storey and Tibshirani, 2003). Eighteen polymorphisms, occurring at
12 unique codons, were associated with at least one Nef function (all
po0.05, qo0.25) (Table 1). No codon was associated with more than
two Nef functions, suggesting that, in general, the secondary (vari-
able) residues and domains that mediate Nef‘s various activities may
also be largely genetically separable. No polymorphisms associated
with HLA-I down-regulation activity were identiﬁed at qo0.25,
therefore we are unable to conﬁrm the novel mutations recently
identiﬁed in chronic infection by Lewis et al. (2012). However, Y135F,
which was previously shown to impair HLA-I down-regulation (Lewis
et al., 2012), was associated with higher viral replication in our study.
Interestingly, variation at Nef codon 21, (within the highly conserved
basic amino acid motif R17RRR22 involved in membrane target-
ing of Nef (Fackler et al., 2006) and vesicle secretion (Ali et al., 2010)),
was associated with lower Nef-mediated viral infectivity and CD74
up-regulation. Future studies will be necessary to elucidate potential
mechanisms for these newly identiﬁed Nef polymorphisms.
Some limitations of our study merit mention. In contrast to
previous reports that evaluated speciﬁc Nef functions using
quasispecies-derived sequences or multiple clones from smaller
numbers of patients (Gray et al., 2011; Lewis et al., 2008), we
aimed to evaluate the dynamic range and co-dependencies of a
broader array of Nef activities using a larger number of patients.
As such, our analysis was limited to a single Nef clone per patient.
Although each patient sequence was closely related to the bulk
plasma RNA sequence (Supplemental Fig. 1), we cannot rule out
selection bias in the clones tested; however, we believe this to be
minimal since most clones were polyfunctional. Second, we
employed recombinant virus approaches to assess most Nef
functions. This method might be limited by incompatibilities
between insert and backbone; however, we did not observe
signiﬁcant differences in p24 antigen production among viral
stocks (data not shown). Finally, to eliminate potential confound-
ing effects due to other HIV-1 proteins, we assessed CD4 down-
regulation function using transient transfection assays. This
approach can be affected by Nef expression or cytotoxicity;
however, we saw no signiﬁcant differences in steady-state protein
levels by Western blot or in cell death by propidium iodide
staining between clones (data not shown). Despite these limita-
tions, our study provides an important quantitative assessment of
the dynamic range and functional co-dependencies for ﬁve of
Nef‘s activities in naturally occurring patient-derived sequences.Conclusion
Nef sequences from chronic HIV-1 infection are in general
highly polyfunctional with respect to enhancement of virion
infectivity, stimulation of viral replication in PBMC, down-
regulation of CD4 and HLA-I, and up-regulation of CD74. The
dynamic ranges of CD4 and HLA-I down-regulation function were
relatively narrow, whereas those for virion infectivity, stimulation
of viral replication in PBMC, and up-regulation of CD74 were
broader. An inverse association was observed between Nef-
mediated enhancement of virion infectivity and CD4þ T-cell
count, indicating the potential biological importance of this Nef
activity in HIV-1 pathogenesis. Strong functional co-dependencies
and the polyfunctional nature of patient-derived Nef sequences
suggest a phenotypic requirement to maintain multiple Nef
functions in vivo during chronic HIV-1 infection.
Methods
Forty-six untreated chronic subtype B infected individuals
(median [IQR] plasma viral load 90,850 [28,840–231,000]copies/ml; CD4þ T-cell count 297.5 [72–455] cells/mm3) were
recruited in the Boston area with written informed consent
(Brumme et al., 2011; Miura et al., 2009). Nef was ampliﬁed from
plasma HIV-1 RNA by nested RT-PCR as described (Miura et al.,
2008) and cloned into the pIRES2-EGFP vector (Clontech). A
median of three Nef clones was sequenced per patient; a single
clone with an intact Nef reading frame that clustered with the
original bulk sequence was selected for analysis (GenBank acces-
sion numbers: JX440926–JX440971).
Nef clones were sub-cloned into a pNL43-DNef plasmid as
described previously (Ueno et al., 2008). As a control, pNL4.3
harboring nef from strain SF2 was used (Ueno et al., 2008).
Proviral clones were transfected into HEK-293T cells and culture
supernatant containing infectious virions was collected 48 h later.
Nef protein expression was veriﬁed by Western blot using two
different polyclonal primary antibodies as described previously
(Mwimanzi et al., 2011, 2013).
With the exception of CD4 down-regulation activity (see
below), all Nef functions were determined using this panel of
recombinant viruses. Infectivity was determined by exposing
TZM-bl cells to virus (3 ng p24Gag) followed by chemilumines-
cence detection as described previously (Wei et al., 2002). Viral
replication kinetics were analyzed by infecting 106 fresh PBMC
from four HIV-seronegative donors with virus (10 ng p24Gag),
followed by stimulation with phytohemagglutinin three days
later. Replication was monitored by p24Gag ELISA over 12 days
and results expressed as the Day 9 p24Gag reading (Ueno et al.,
2008). To assess Nef-mediated HLA-I down-regulation and CD74
up-regulation, 721.221 cells stably expressing CD4 and HLA-
An24:02 were exposed to virus (300 ng p24Gag) for 48 h, followed
by staining with PE-labeled anti-HLA-A24 mAb (MBL), Alexa-647
anti-human CD74 mAb (BioLegend), 7-amino-actinomycin D
(BioLegend), and FITC-labeled anti-p24Gag mAb (KC57-FITC, Beck-
man Coulter) as previously described (Mwimanzi et al., 2013).
Fluorescence intensity of each receptor in p24Gag-positive and
negative live cells was determined by ﬂow cytometry.
Nef-mediated CD4 down-regulation was assessed by electro-
poration of CEM T cells with Nef-expression plasmids as pre-
viously described (Mwimanzi et al., 2013). At 24 h, transfected
cells were stained with allophycocyanin-labeled anti-CD4 anti-
body (BD Biosciences). Median ﬂuorescence intensity for CD4 was
determined by ﬂow cytometry (Millipore Guava 8HT).Acknowledgments
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